Benlysta (belimumab) works by blocking a specific protein your immune system uses to keep certain white blood cells alive. In lupus, these cells overproduce antibodies that mistakenly attack your own tissues. By cutting off their survival signal, Benlysta gradually reduces the number of these problematic cells, dialing down the autoimmune activity that drives lupus symptoms.
The Protein Benlysta Targets
Your immune system produces a protein called BLyS (B-lymphocyte stimulator, also known as BAFF). BLyS acts as a survival signal for B cells, a type of white blood cell responsible for making antibodies. In healthy people, BLyS helps maintain a balanced immune defense. In people with lupus, BLyS levels are elevated, which keeps too many B cells alive, including ones that produce autoantibodies targeting the body’s own organs, joints, and skin.
Benlysta is a human monoclonal antibody, meaning it’s an engineered protein designed to latch onto one very specific target. It binds to soluble BLyS floating in the bloodstream and prevents it from connecting with receptors on the surface of B cells. Without that survival signal, excess B cells lose their lifeline and undergo apoptosis, or programmed cell death. This is not the same as wiping out the immune system. It’s a targeted reduction of the overactive B cells fueling the disease.
What Happens to B Cells Over Time
The effects of Benlysta on B cells are gradual and cumulative. During the first six months, some B cell types (particularly memory B cells) actually rise temporarily before beginning a sustained decline. This initial increase is normal and doesn’t mean the drug isn’t working.
Over longer treatment periods, the reductions become significant. In a study tracking patients through six years of continuous treatment, circulating B cell counts dropped by 83% to 92% across major subtypes. Activated B cells and a subset called plasmacytoid B cells saw the steepest drops, falling 98% to 99%. Memory B cells declined by about 67%, and certain plasma cells linked to lupus activity dropped 40% to 50%. Importantly, no B cell subset was completely eliminated. The immune system retains enough B cells to provide baseline defense against infections, though it is somewhat more vulnerable.
Most of these declines plateaued after about five to six years of treatment, though memory B cells continued a slow, steady decrease beyond that point.
Measurable Changes in Lupus Activity
One of the clearest ways to see Benlysta working is through blood markers that track lupus activity. Anti-dsDNA antibodies, a hallmark of active lupus, dropped by roughly 37% to 41% after one year of treatment, compared to just 10% with placebo. These reductions appeared as early as eight weeks in and held steady through the full year.
Complement proteins C3 and C4, which are consumed during immune attacks and run low in active lupus, also improved. Patients who started with depleted complement levels saw significant increases within four weeks. Patients on placebo were far more likely to see their complement levels drop further or their anti-dsDNA antibodies rise during the same period. These biomarker shifts reflect the core mechanism at work: fewer rogue B cells means fewer autoantibodies, which means less immune-driven damage.
How Well It Works in Clinical Trials
Benlysta has been tested in several large trials for both general lupus (systemic lupus erythematosus, or SLE) and lupus nephritis, which is lupus-related kidney disease. In the major SLE trials, patients on Benlysta achieved meaningful disease improvement at rates of 43% to 58%, compared to 34% to 44% with placebo. The benefit was consistent across studies involving both adults and children.
For lupus nephritis, the BLISS-LN trial measured kidney-specific responses over two years. At one year, 47% of patients on Benlysta had a positive kidney response versus 35% on placebo. At two years, the numbers were 43% versus 32%. These are meaningful differences for a disease where kidney damage can progress to organ failure, though they also show that Benlysta doesn’t work for everyone.
How It’s Given
Benlysta is approved for patients aged 5 and older with active SLE or lupus nephritis. It comes in two forms: intravenous infusion and subcutaneous injection.
The IV infusion is dosed by body weight at 10 mg/kg. You receive the first three infusions two weeks apart, then switch to once every four weeks. Each infusion is given at a medical facility.
The subcutaneous version is a weekly self-injection of 200 mg for active SLE. For lupus nephritis, treatment starts with a loading phase of 400 mg weekly (two injections) for the first four weeks, then drops to 200 mg weekly. The subcutaneous option gives patients the flexibility to inject at home after initial training.
What to Expect as a Patient
Benlysta is not a fast-acting drug. Because it works by gradually reducing B cell populations rather than suppressing inflammation directly, most patients need several months before noticing meaningful symptom improvement. The biomarker changes that signal the drug is working begin within the first two months, but clinical benefits, like fewer flares and less joint pain, typically follow later. Clinical trials measured outcomes at 52 weeks, and many patients who ultimately responded didn’t separate from placebo until several months into treatment. Patience during the early months is important.
Benlysta is used alongside other lupus medications, not as a replacement for them. Most patients in clinical trials were also taking corticosteroids, antimalarials, or immunosuppressants. One of the goals of adding Benlysta is to eventually reduce steroid doses, since long-term steroid use carries its own serious side effects.
Side Effects and Safety
The overall rate of side effects with Benlysta is similar to placebo, around 95% in both groups in clinical trials, which reflects the high background rate of symptoms in active lupus itself. The side effects that occurred somewhat more often with Benlysta than placebo were urinary tract infections (19% vs. 16%), cough (13% vs. 9%), and upper abdominal pain (6% vs. 3%).
Serious side effects were slightly less common with Benlysta than placebo (26% vs. 30%). Infections are the primary safety concern, which makes sense given that the drug reduces immune cell numbers. Pneumonia was the most common serious infection in both groups. Herpes zoster (shingles) occurred at a modestly higher rate with Benlysta (about 2% vs. 1%). Infusion reactions, like nausea, headache, or skin flushing during IV administration, occurred in roughly 12% of patients in both groups.
Rare but serious risks include severe infections, certain malignancies, and psychiatric effects including suicidal thoughts, though these were uncommon in trials. Because Benlysta lowers immune defenses, screening for active infections (particularly tuberculosis) is standard before starting treatment.